tiprankstipranks

CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBM

CNS Pharmaceuticals down 55% after Berubicin doesn’t show OS superiority in GBM

Shares of CNS Pharmaceuticals (CNSP) are down $1.86, or 55%, to $1.52 in pre-market trading after the company reported that the primary analysis of its clinical trial evaluating Berubicin for the treatment of recurrent or progressive Glioblastoma Multiforme did not demonstrate statistically significant superiority in overall survival, the primary endpoint.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue